Clinical trials: Alcoholic Hepatitis, open to volunteers
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Alcohol Use Disorder, Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant…
- Trial name
- NCT03845205
- Testing
- Integrated AUD Treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Liver Diseases, Alcoholic, Alcohol-Related Disorders
Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
The purpose of this study is to develop a clinical understanding of early liver transplantation (ELT) for patients with severe alcoholic hepatitis (SAH) and identify the public's opinion regarding this practice.
- Conditions
- Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection
- Trial name
- NCT04234139
- Testing
- liver transplant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Johns Hopkins University
Alcoholic Hepatitis
Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis
Patients with acute alcoholic hepatitis will be identified based on national institute on alcohol abuse and alcoholism (NIAAA) will be identified, MELD score will be calculated, patents with MELD score between 20-35 will be…
- Trial name
- NCT06789315
- Testing
- Mycophenolate Mofetil, Prednisone
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Severe Acute Alcoholic Hepatitis, Alcohol
Intestinal Microbiota Profiling in Severe Acute Alcoholic Hepatitis Patients
In humans, alcohol-related dysbiosis exists with a decrease in bacteroides. This dysbiosis is responsible for the breakdown of the intestinal barrier by a decrease in the synthesis of protective mucus, and some proteins involved…
- Conditions
- Severe Acute Alcoholic Hepatitis, Alcohol, Intestinal Microbiota, Corticosteroids
- Trial name
- HepathAlc-IM (NCT06159244)
- Testing
- stool withdrawal
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Alcoholic Hepatitis
HA35 Moderate Alcoholic Hepatitis (AH) Study
Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement…
- Trial name
- NCT05018481
- Testing
- Sodium Hyaluronate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- The Cleveland Clinic
Liver Diseases
Characterization of the Intrahepatic Inflammatory Microenvironment in Patients With Non-alcoholic Steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) is a nosological entity that groups together non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).
- Trial name
- Profil-NASH (NCT06152250)
- Testing
- Liver Fine-Needle Aspiration
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon
Chronic Hepatitis B, Non-alcoholic Fatty Liver Disease
Chronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention.
In Taiwan, HBV infection is endemic in the adult population. With the westernization of eating habit and lifestyle, metabolic syndrome and related non-alcoholic fatty liver diseases (NAFLD, newly proposed as metabolic dysfunction…
- Trial name
- NCT05956379
- Testing
- exercise
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Severe Alcoholic Hepatitis
LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis
Background \& Rationale Severe alcohol-related hepatitis (SAH) is a serious condition with a 3-month mortality rate of ~30%. Diagnosis and prognosis are complex due to non-specific and insensitive clinical, biological, and…
- Trial name
- Liver TREM-1 (NCT07176741)
- Testing
- TREM-1 expression (via immunohistochemistry) between SAH patients and controls
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C
Blood Collection Biorepository for Liver Disease Research
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the…
- Conditions
- Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis
- Trial name
- NCT03025074
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05766449
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Acute Alcoholic Hepatitis
Integrative Epidemiology of Prognosis in Patients With Acute Alcoholic Hepatitis at AP-HP
Acute alcoholic hepatitis (AAH) is a severe liver disease that often occurs in individuals with prolonged excessive alcohol consumption.
- Trial name
- DIONYSOS (NCT07262515)
- Where
- France
- Volunteers
- 1,400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis, Cirrhosis, Liver
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
- Conditions
- Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
- Trial name
- LCN RESCU (NCT05832229)
- Testing
- Rosuvastatin
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic…
- Trial name
- NCT06368882
- Testing
- Peg-Interferon α
- Where
- 5 sites in China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).
- Trial name
- NCT02863757
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Humanity and Health Research Centre
Liver Fibrosis, Liver Cirrhosis
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness
Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease.
- Conditions
- Liver Fibrosis, Liver Cirrhosis, NAFLD (Nonalcoholic Fatty Liver Disease), HEPATITIS B CHRONIC
- Trial name
- NCT07716384
- Testing
- Wearable Patch-Type Ultrasound Probe, Transient Elastography (FibroScan)
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
the Effect of NAFLD on CHB
A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease.
This is a prospective/retrospective, observational follow-up study of effects of fatty liver on chronic hepatitis B. Patients will join this study who undergo transient elastography with liver stiffness (LS) and CAP measurements…
- Trial name
- NCT05255978
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Qin Ning
Alcoholic Hepatitis, Acute Alcoholic Hepatitis
MRG-001 in Patients With Alcoholic Hepatitis
The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis…
- Trial name
- NCT06307522
- Testing
- MRG-001
- Volunteers
- 32 people
- Sponsor
- MedRegen LLC
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals